AI helps Non-Experts perform heart scans in rare heart condition

NCT ID NCT07155434

Terminated Knowledge-focused Sponsor: UltraSight Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether healthcare workers without ultrasound training could use AI software to perform heart scans on people with hypertrophic obstructive cardiomyopathy (HOCM) who are eligible for the drug mavacamten. Participants had two scans on the same day: one by a non-specialist using the AI guidance and one by a trained sonographer. The goal was to see if the AI-assisted scans were good enough to monitor heart function, potentially making it easier for patients to get regular check-ups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: UltraSight AI guidance software
What this could lead to: If successful, this could allow more patients to get heart scans without needing a specialist, making monitoring easier and more accessible.
What could go wrong: This was a small, terminated study, so results may not be reliable. AI-guided scans may not match the quality of trained sonographers, limiting real-world use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIAC IMAGING are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hypertrophic cardiomyopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARDIAC IMAGING ECHOCARDIOGRAPHY HYPERTROPHIC CARDIOMYOPATHY (HCM) MAVACAMTEN OBSTRUCTIVE CARDIOMYOPATHY, HYPERTROPHIC

Contacts and locations

Locations

Cleveland Clinic, Cardiovascular Medicine Department

Cleveland, Ohio, 44195, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.